[Activation of autologous hematopoietic stem cell transplants with interleukin-2].
BACKGROUND
Recent findings of the role of the immunity in eradication of residual tumour tissue after autologous transplantation rejection leading to extensive studies on T-cell mediated specific antitumor effects or nonspecific NL-cell mediated anticancer effects. We have evaluated on the methods of adoptive cell therapy--IL-2 activation of autologous graft in the preclinical conditions. In laboratory conditions we have manipulated with autologous grafts form patients suffering with chronic myelocytic leukemia and patients suffering with multiple myeloma.


RESULTS
Autologous graft was activated with IL-2 during 24-hours cultivation period in X-Vivo 10 medium with heparine, glutamine and Dnase. Quality of grafts after cultivation, contamination and activation of T and NK cell were evaluated. No significant differences between IL-2 activated graft and control were found. Results of autologous graft quality (CD34+, CFU-GM) were comparable with already published results. Quality of final product allowed starting of clinical experimental trials.


CONCLUSIONS
We have proved the possibility to use IL-2 activated autologous graft in the clinical conditions. Based on our preclinical results experimental clinical trials have been initiated in patients suffering from chronic myelocytic leukemia and multiple myeloma.
Hájek
R
R
Interní hematoonkologická klinika FN, Brno-Bohunice. r.hajek@fnbrno.cz
Korístek
Z
Z
Vinklárková
J
J
Janovská
E
E
Klabusay
M
M
Doubek
M
M
Dvoráková
D
D
Bourková
L
L
Dusek
L
L
Adler
J
J
Mayer
J
J
Vorlícek
J
J
D002478:Cells, Cultured; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000276:immunology* / Q000494:pharmacology; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000628:therapy*; D009101:Multiple Myeloma / Q000276:immunology / Q000628:therapy*
D007376:Interleukin-2